EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SCN1A pathogenic variants do not have a distinctive blood‐derived DNA methylation signature

Christy W LaFlamme iD, Karim Karimi, Cassandra Rastin, Edith P Almanza Fuerte, Talia Allan, Sophie J Russ-Hall, Amy L Schneider iD, Daniel Stobo, Gaetan Lesca iD, Joseph D Symonds iD, Andreas Brunklaus, Lynette G Sadleir iD und 3 weitere

Epilepsia · 2025

DOI: 10.1111/epi.18315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Christy W LaFlamme und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology, Center for Pediatric Neurological Disease Research, St. Jude Children's Research Hospital, Memphis, Tenness…. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, DNA Methylation, Epilepsies, Myoclonic. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Epilepsy Society, Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA methylation signatures (“episignatures”) can be used as biomarkers of genetic aberrations, clinical phenotypes, and environmental exposures in rare diseases. Episignatures are utilized in molecular diagnostics and can clarify variants of uncertain significance. A growing number of disease genes, including epilepsy genes, exhibit robust and reproducible episignatures. However, whether SCN1A , the most prominent epilepsy gene, has one or more episignatures has not yet been determined. We generated genome‐wide DNA methylation data and performed episignature analysis on 64 individuals with Dravet syndrome due to pathogenic loss‐of‐function (LOF) variants in SCN1A and seven individuals with early infantile SCN1A developmental and epileptic encephalopathy due to pathogenic gain‐of‐function (GOF) variants in SCN1A , relative to a large reference database of controls and rare disease episignature‐positive cohorts. We analyzed all samples with LOF variants together and performed separate analyses for missense, nonsense, and GOF variant cohorts. A reproducible blood‐derived episignature was not evident in any of the cohorts using current analytical approaches and reference data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.1 Voltage-Gated Sodium ChannelDNA MethylationEpilepsies, MyoclonicHumansMaleFemaleChildCohort StudiesInfantChild, PreschoolGenome-Wide Association Study

Stichwörter der Autor:innen

SCN1ADNA methylationDravet syndrome

Substanzen

NAV1.1 Voltage-Gated Sodium ChannelSCN1A protein, human

Autor:innen und Institutionen

  • Department of Cell and Molecular Biology, Center for Pediatric Neurological Disease Research, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Department of Medicine, Epilepsy Research Centre, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
  • West of Scotland Centre for Genomic Medicine, Queen Elizabeth University Hospital, Glasgow, UK.

ORCID-Profile: Christy W LaFlamme, Amy L Schneider, Gaetan Lesca, Joseph D Symonds, Lynette G Sadleir, Heather C Mefford

Förderung

  • American Epilepsy Society
  • Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence
  • National Health and Medical Research Council

Zitieren

APA

LaFlamme, C. W., Karimi, K., Rastin, C., Almanza Fuerte, E. P., Allan, T., Russ-Hall, S. J., Schneider, A. L., Stobo, D., Lesca, G., Symonds, J. D., Brunklaus, A., Sadleir, L. G., Scheffer, I. E., Sadikovic, B., & Mefford, H. C. (2025). SCN1A pathogenic variants do not have a distinctive blood‐derived DNA methylation signature. Epilepsia. https://doi.org/10.1111/epi.18315

Vancouver

LaFlamme CW, Karimi K, Rastin C, Almanza Fuerte EP, Allan T, Russ-Hall SJ, et al. SCN1A pathogenic variants do not have a distinctive blood‐derived DNA methylation signature. Epilepsia. 2025. doi:10.1111/epi.18315

BibTeX
@article{LaFlamme2025,
  author = {LaFlamme, Christy W and Karimi, Karim and Rastin, Cassandra and Almanza Fuerte, Edith P and Allan, Talia and Russ-Hall, Sophie J and Schneider, Amy L and Stobo, Daniel and Lesca, Gaetan and Symonds, Joseph D and Brunklaus, Andreas and Sadleir, Lynette G and Scheffer, Ingrid E and Sadikovic, Bekim and Mefford, Heather C},
  title = {SCN1A pathogenic variants do not have a distinctive blood‐derived DNA methylation signature},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18315}
}
Kostenlos starten →